How can you improve antidepressant adherence?

Talk to your patients about side effects and how long treatment will take

Practice recommendations

- Educating your patients on how to take their antidepressant medication helps adherence.
- Primary care physicians may be able to improve patient adherence to antidepressant medications by telling patients how long they will have to take them, letting them know about possible side effects, and addressing their questions and concerns.

Nonadherence to antidepressants among patients with depressive disorders has been reported to be as high as 68%.1 While research on the efficacy and effectiveness of depression treatments is voluminous, research on factors associated with antidepressant adherence is much more limited.2,3 Several studies have pointed to the importance of patient education regarding antidepressants in improving adherence.4,5 Previous studies have found that rates of antidepressant adherence4 and medication discontinuation6 were significantly associated with the how much information the physician gave the patient about the drug's use. However, a review of interventions to improve adherence concluded that patient education required further study.6

In this study, we prospectively examined whether patient reports of specific educational messages from their primary care physician on antidepressant usage was associated with medication adherence during the first 3 months of treatment. To monitor adherence, we used electronic monitoring caps rather than self-report. Based upon prior work examining predictors of adherence,4 we hypothesized that patients who received specific messages about how to take their medicine would demonstrate greater adherence during the first 3 months of treatment.

Implications

Findings support hypothesis

We found a significant dropoff in adherence to prescribed antidepressants during the first 3 months of treatment. We also found support for our hypothesis that patients who received specific messages from their physicians would be more adherent to their drug regimen. We were able to identify several key messages that were associated with at least 80% adherence over a 3-month period. The most important messages were: How long the patient should expect to take the medicine and what to do if there are questions. Other important messages included being told to keep taking the medication even if feeling better, being advised as to how long side effects would last, and being given advice on managing minor side effects.

Charlotte Brown, PhD, Deena R. Battista, PhD
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pa
brownctupmc.edu

Susan M. Sereika, PhD
University of Pittsburgh School of Nursing, Pittsburgh, Pa

Richard D. Bruehlman, MD
Renaissance Family Practice, Pittsburgh, Pennsylvania; Department of Family Medicine and Epidemiology, University of Pittsburgh School of Medicine

Jacqueline Dunbar-Jacob, PhD
University of Pittsburgh School of Nursing

Michael E. Thase, MD
Department of Psychiatry, University of Pittsburgh School of Medicine

Charlotte Brown, PhD, Deena R. Battista, PhD
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pa
brownctupmc.edu

Susan M. Sereika, PhD
University of Pittsburgh School of Nursing, Pittsburgh, Pa

Richard D. Bruehlman, MD
Renaissance Family Practice, Pittsburgh, Pennsylvania; Department of Family Medicine and Epidemiology, University of Pittsburgh School of Medicine

Jacqueline Dunbar-Jacob, PhD
University of Pittsburgh School of Nursing

Michael E. Thase, MD
Department of Psychiatry, University of Pittsburgh School of Medicine

Charlotte Brown, PhD, Deena R. Battista, PhD
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pa
brownctupmc.edu

Susan M. Sereika, PhD
University of Pittsburgh School of Nursing, Pittsburgh, Pa

Richard D. Bruehlman, MD
Renaissance Family Practice, Pittsburgh, Pennsylvania; Department of Family Medicine and Epidemiology, University of Pittsburgh School of Medicine

Jacqueline Dunbar-Jacob, PhD
University of Pittsburgh School of Nursing

Michael E. Thase, MD
Department of Psychiatry, University of Pittsburgh School of Medicine

Charlotte Brown, PhD, Deena R. Battista, PhD
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pa
brownctupmc.edu

Susan M. Sereika, PhD
University of Pittsburgh School of Nursing, Pittsburgh, Pa

Richard D. Bruehlman, MD
Renaissance Family Practice, Pittsburgh, Pennsylvania; Department of Family Medicine and Epidemiology, University of Pittsburgh School of Medicine

Jacqueline Dunbar-Jacob, PhD
University of Pittsburgh School of Nursing

Michael E. Thase, MD
Department of Psychiatry, University of Pittsburgh School of Medicine

Copyright © Dowden Health Media
For personal use only. For mass reproduction, content licensing and permissions contact Dowden Health Media.
Methods

Participants
We enrolled 191 primary care patients in a year-long observational study. All participants were referred to the parent study by their primary care physicians.

Patients were eligible for referral if they were age 18 years or older; had been prescribed an antidepressant for the treatment of depression in the preceding 2 weeks or had been switched to a new antidepressant within the preceding 2 weeks; had no lifetime history of bipolar disorder; had no substance abuse or dependence in the preceding 6 months; or had no current psychotic symptoms or history of psychotic disorder. The study protocol was approved by the University of Pittsburgh Institutional Review Board and the Veteran’s Affairs Institutional Review Board. All participants provided written informed consent.

Participants were recruited from 2 urban family practice health centers: a single-specialty group practice and 2 primary care clinics in the Veterans Health Administration (VHA). This report focuses on data obtained through interviews and questionnaires at the baseline evaluation (n=191) and adherence data from the first 3 months of the study (n=178).

Measures
Information on race, gender, education, employment, marital status, and income was obtained from each participant. A semistructured interview was administered to assess the presence of current mood, anxiety, substance use, and somatoform disorders.

Severity of depressive symptoms was evaluated with the 21-item Beck Depression Inventory. Psychosocial and physical functioning was assessed with the 36-item, self-administered Medical Outcomes Study Short Form General Health Survey (MOS SF-36). The MOS scales were weighted and aggregated into the scores for the Physical Component Scale (MOS PCS) and the Mental Component Scale (MOS MCS).

Medical conditions were assessed with a modified version of a checklist developed by Wells et al for use in the Medical Outcomes Study. The modified list assessed the presence of hypertension, diabetes, coronary artery disease, arthritis, back problems, pulmonary problems, gastrointestinal disorders, cancer in the preceding 3 years, major neurological problems, cardiac pacemaker, kidney disease, legal blindness, eye disease, thyroid disease, lupus, and HIV/AIDS.

Electronic caps track adherence
At baseline, patients were given their medications in bottles with electronic monitoring caps. The Medication Event Monitoring System (MEMS) cap made

| TABLE 1 |
| Baseline demographic, clinical characteristics, and diagnoses of enrolled sample (N=191) |

<table>
<thead>
<tr>
<th>DEMOGRAPHICS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) age</td>
<td>45.1 (15.9)</td>
</tr>
<tr>
<td>% Female</td>
<td>70.7</td>
</tr>
<tr>
<td>% White</td>
<td>93.7</td>
</tr>
<tr>
<td>% Employed full/part-time</td>
<td>52.9</td>
</tr>
<tr>
<td>% Married or living with partner</td>
<td>53.9</td>
</tr>
<tr>
<td>% Greater than high school education</td>
<td>55.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CLINICAL CHARACTERISTICS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) BDI</td>
<td>19.5 (10.3)</td>
</tr>
<tr>
<td>Mean (SD) MOS PCS</td>
<td>44.6 (11.5)</td>
</tr>
<tr>
<td>Mean (SD) MOS MCS</td>
<td>30.7 (10.7)</td>
</tr>
<tr>
<td>Mean (SD) number of current medical conditions</td>
<td>2.0 (1.6)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MOOD DIAGNOSIS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>No diagnosis</td>
<td>13.6%</td>
</tr>
<tr>
<td>Major depression only</td>
<td>36.6%</td>
</tr>
<tr>
<td>Major depression + dysthymia</td>
<td>30.4%</td>
</tr>
<tr>
<td>Partial remission of major depression</td>
<td>6.3%</td>
</tr>
<tr>
<td>Partial remission of major depression + dysthymia</td>
<td>7.9%</td>
</tr>
<tr>
<td>Dysthymia only</td>
<td>1.6%</td>
</tr>
<tr>
<td>Minor depression only</td>
<td>3.7%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMORBIDITY (MOOD + ANXIETY)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>–Major depression or dysthymia + panic or generalized anxiety disorder</td>
<td>27.7%</td>
</tr>
<tr>
<td>–Any mood disorder + any anxiety disorder</td>
<td>50.3%</td>
</tr>
</tbody>
</table>

BDI, Beck Depression Inventory; MOS MCS, Medical Outcomes Study Short Form Mental Component Score; MOS PCS, Medical Outcomes Study Short Form Physical Component Score.
The enrolled sample was predominantly female, white, and had a mean age of 45 years. More than half had some college education, were married (or living with a partner), and were employed full- or part-time (TABLE 1).

**Clinical characteristics**

On average, patients reported 2 medical conditions (moderate symptoms of depression, and moderate impairment in psychosocial functioning). All participants referred to the study had been prescribed an antidepressant for the treatment of depression by their primary care physician.

At the initial interview, 67% of patients met Diagnostic and Statistic Manual, 4th ed (DSM-IV) criteria for major depression. Approximately 37% met criteria for major depression alone, while 30% met criteria for major depression and dysthymia. Four percent met the criteria for minor depression, 6% were in partial remission of major depression, and 14% of participants did not meet criteria for a DSM-IV mood disorder. Comorbid anxiety disorders were common in this sample; 28% of participants with major depression or

### Results

Nearly one-third of the patients were taking citalopram, followed by 19% on fluoxetine.
Dysthymia had comorbid generalized anxiety disorder or panic disorder. More than 80% of the antidepressants the patients were taking were selective serotonin reuptake inhibitors (SSRIs). Citalopram (31%), fluoxetine (19%), paroxetine (15%), and sertraline (13%) were the most common (Table 2).

**Adherence declines over 3 months**
Overall, adherence to antidepressants significantly decreased over time. While adherence as measured by the percentage of prescribed doses taken was good (82%) at month 1, it showed a significant linear decrease to 69% at 3 months ($P<.0001$).

When the more stringent measure of adherence was examined—ie, percentage of days with correct intake and timing—adherence was even poorer, decreasing nonlinearly over time. Adherence at month 1 was only 55%; and decreased to 43% at 3 months (linear: $P<.001$; quadratic: $P=.036$). Our findings indicate that by the end of the first 3 months of treatment, between about one-third and one-half of the patients were nonadherent to their regimen.

### Univariate predictors of adherence

**Adherent patients are older**
Medication adherence of at least 80% was used as a cutpoint; ≥80% was considered adherent, <80% nonadherent. Univariate analyses ($t$-tests and chi-square tests) indicated that the following patient characteristics were significantly associated with taking the correct number of prescribed antidepressant doses at least 80% of the time within the first 3 months of treatment.

- **Age**—adherent patients were significantly older than nonadherent ($P=.01$)
- **Race**—whites were more adherent than nonwhites (67% vs 0%; $P=.001$)
- **Gender**—men were more adherent than women (81% vs 56%; $P=.03$)
- **Depression severity**—adherent patients had milder depressive symptoms than nonadherent patients ($P=.04$).

### Table 3

<table>
<thead>
<tr>
<th>PATIENTS RECEIVING DISCUSSION</th>
<th>ADHERENCE (YES ≥80%)</th>
<th>DOSES TAKEN OVER 3 MONTHS (%)</th>
<th>DAYS WITH CORRECT INTAKE AND TIMING OVER 3 MONTHS (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EDUCATION ITEM</strong></td>
<td>% (n)</td>
<td>NO</td>
<td>YES</td>
</tr>
<tr>
<td>Take on a daily basis</td>
<td>79.2 (152)</td>
<td>75.0</td>
<td>83.1</td>
</tr>
<tr>
<td>Told how long medication would take to work</td>
<td>75.5 (145)</td>
<td>69.0</td>
<td>81.5</td>
</tr>
<tr>
<td>Told what to do if there were questions</td>
<td>75.5 (145)</td>
<td>66.7</td>
<td>86.2</td>
</tr>
<tr>
<td>Asked about prior use of similar medicine</td>
<td>71.4 (137)</td>
<td>71.4</td>
<td>73.8</td>
</tr>
<tr>
<td>Don’t stop taking without checking with office</td>
<td>63.0 (121)</td>
<td>56.0</td>
<td>69.2</td>
</tr>
<tr>
<td>Given simple explanation of how medicine works</td>
<td>59.4 (114)</td>
<td>54.8</td>
<td>63.1</td>
</tr>
<tr>
<td>Keep taking even if feeling better</td>
<td>58.9 (113)</td>
<td>48.8</td>
<td>64.6</td>
</tr>
<tr>
<td>Discussed common side effects</td>
<td>46.9 (90)</td>
<td>41.7</td>
<td>47.7</td>
</tr>
<tr>
<td>Advised on what to do if there are major side effects</td>
<td>30.2 (58)</td>
<td>28.6</td>
<td>29.2</td>
</tr>
<tr>
<td>Told how long to expect to take this medicine</td>
<td>29.2 (56)</td>
<td>16.7</td>
<td>38.5</td>
</tr>
<tr>
<td>Advised of how long side effects will last</td>
<td>28.6 (55)</td>
<td>23.8</td>
<td>32.3</td>
</tr>
<tr>
<td>Given advice on managing minor side effects</td>
<td>27.1 (52)</td>
<td>23.8</td>
<td>30.8</td>
</tr>
</tbody>
</table>

**FAST TRACK**

Univariate analyses revealed that men were more adherent than women.
When percentage of days with correct intake and timing was examined, depressive severity was the only variable that differentiated adherent from nonadherent patients. Individuals who had at least 80% adherence over the first 3 months initially presented with milder depressive symptoms at the baseline evaluation ($P=.02$). Other demographic and clinical characteristics did not differentiate adherent from nonadherent patients.

**Regimen duration discussions linked to better adherence**

Several key messages about antidepressant medication differentiated adherent from nonadherent patients (TABLE 3). For percentage of prescribed doses taken during a 90-day period, the key messages differentiating adherent from nonadherent patients were “told what to do if there were questions,” “keep taking the medication even if feeling better,” and “told how long to expect to take medicine.”

For the more stringent measure of adherence (percentage of days with correct intake and timing), 4 key messages differentiated adherent from nonadherent patients: “told what to do if there were questions,” “told how long to expect to take medicine,” “advised of how long side effects will last,” and “given advice on managing minor side effects.”

**Discussion**

**Physician messages tied to adherence**

Consistent with prior reports, we found a significant decrease in adherence to prescribed antidepressants during the first 3 months of treatment. However, physicians’ educational messages about how to take the antidepressant were significantly associated with adherence in both univariate and multivariate analyses.

While more than three-quarters of study participants indicated that they were told to take the medication daily, how long it would take to work, and what to do if there were questions, the least frequently reported messages involved managing side effects, with less than a third of patients indicating that their physician had discussed this with them. The latter finding is important because univariate analyses indicated that discussion of side effects was significantly associated with adherence during the first 3 months of treatment.

In multivariate analyses, we were able to further identify those key messages that were associated with at least 80% adherence over a 3-month period. A unique aspect of our study is the use of electronic monitoring to measure adherence, which provides detailed information on the exact
time patients took their medication and allowed us to identify predictors associated with more conservative (percentage of days with correct intake and timing) and less conservative (percentage of prescribed doses taken) measures of adherence. Our findings suggest that primary care physicians may be able to improve adherence by providing simple and specific information about using antidepressants. The most important of these being “how long to expect to take the medicine” and “what to do if there are questions.”

**Limitations of this study**

Our findings are limited to primary care patients from 3 types of primary care settings—private offices, university-based clinics, and VA clinics. These findings may not generalize to other types of family practice or primary care settings such as large managed care organizations, publicly funded primary care settings, and so on.

Also, it’s important to note that we did not assess what physicians actually told patients; we only inquired about those messages that patients recalled. However, the information actually recalled seems more likely to influence their behavior.

In addition, because we did not perform direct observation of the physician-patient interaction, we were unable to control for other possible confounders. For example, physicians who communicate more effectively may have a positive effect on adherence through some other aspect of communication than the specific messages measured.11

Finally, we did not assess patient-related factors such as health literacy. Patients with low functional health literacy may have lower recall of information provided during the visit and may have lower levels of adherence.

**Keeping our sights on patient education**

Future studies are needed to assess patient’s literacy and record physicians’ actual communications and patients’ self-reports of such information in order to determine the impact of such factors. Nevertheless, our findings provide useful information about educational messages that physicians—as well as nurses—can provide to improve antidepressant adherence. ■

**Correspondence**

Charlotte Brown, PhD, Department of Psychiatry, University of Pittsburgh School of Medicine, 3811 O’Hara Street, Pittsburgh, Pa, 15213 browncl@upmc.edu

**Acknowledgments**

This research was supported by a grant from the National Institute of Mental Health (R01 MH60763) to Charlotte Brown, PhD. The authors thank the physicians and medical staff of Renaissance Family Practice, University of Pittsburgh-St. Margaret’s Family Practice Residency Program, and the Veteran’s Health Administration Primary Care Clinics for their assistance in the recruitment of study participants. Special thanks goes out to Sarah Stephen, MSW, LSW, Nicole Ryan, BA, and Janine Smith, BS, for their technical assistance.

**Disclosure**

Dr Thase has served as an advisor/consultant/speaker for AstraZeneca, Bristol-Meyers Squibb, Cephalon, Cyberonics, Eli Lilly, GlaxoSmithKline, Janssen, MedAvante, Neurotechne, Novartis, Organon, Sanofi Aventis, Sepracor, Shire US, and Wyeth. The other authors report no potential conflict of interest relevant to this article.

**References**